The Phase I/IIa clinical trial is a multinational, multi-center, single and multiple dose, tolerability, safety and pharmacokinetic trial of CMND-100 in healthy volunteers and AUD subjects. For further information visit: https://www.clearmindmedicine.com or contact: General Inquiries "The FDA's IND approval for CMND-100 marks a significant step forward in addressing the critical unmet medical needs in AUD, a disease currently lacking effective treatments. Excessive alcohol use is a leading preventable cause ...

"The FDA's IND approval for CMND-100 marks a significant step forward in addressing the critical unmet medical needs in AUD, a disease currently lacking effective treatments. Excessive alcohol use is a leading preventable cause of death in the United States, affecting millions of patients and their families. We believe in the potential of our treatment to improve millions of lives in a safe, easy, and efficient way," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "Approval to start our first-in-human ...

Core Viewpoint - Clearmind Medicine Inc. has submitted an additional patent application to the USPTO as part of its collaboration with SciSparc Ltd. to develop novel psychedelic-derived therapeutics aimed at addressing under-treated health issues, including obesity and addiction [1][3][4]. Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to tackle significant health problems, particularly alcohol use disorder [4]. - The company currently holds an intellectual property portfolio consisting of eighteen patent families, including 28 granted patents, and aims to expand its patent holdings opportunistically [10]. Collaboration and Patent Applications - In collaboration with SciSparc, Clearmind has filed a total of twelve patent applications with the USPTO for various proprietary compositions, including the combination of SciSparc's PEA and Clearmind's MEAI compound for treating alcohol use disorder, cocaine addiction, and obesity [3][8]. - The latest patent application specifically refers to the proprietary composition of Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for addressing metabolic syndrome and obesity [8]. Market Context - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a rapid revenue CAGR of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [9].

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and Trademark Office ("USPTO") was submitted as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind"), a clinical-st ...

Company Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [4][5] - The company has filed multiple patent applications in collaboration with SciSparc Ltd. for various proprietary compositions aimed at treating alcohol use disorder, cocaine addiction, obesity, and related metabolic disorders [3][5] Market Insights - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [2] Intellectual Property - Clearmind's intellectual property portfolio includes eighteen patent families with 28 granted patents, and the company plans to pursue additional patents as opportunities arise [7] - A recent patent application pertains to a novel composition combining Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for treating metabolic syndrome and obesity [6]

Core Insights - Clearmind Medicine Inc. is participating in the Psychedelic Medicine – Israel 2024 conference, which will take place from July 28th to 30th in Tel Aviv, Israel, focusing on psychedelic medicine advancements [1][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [9] - The company currently holds an intellectual property portfolio consisting of eighteen patent families and 28 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [4] Research Presentations - Notable presentations at the conference include research on 5-methoxy-2-aminoindane (MEAI), a mild psychedelic agent, which has shown potential in reducing diet-induced obesity and regulating binge behaviors [6][11] - Dr. Zullof-Shani, CEO of Clearmind, will present on MEAI's potential as a binge behavior regulator, highlighting its innovative application in addiction treatment [8][11] - Research findings indicate that MEAI significantly reduces fat mass, preserves lean mass, improves glucose metabolism, reduces hepatic steatosis, and increases energy expenditure in a diet-induced obesity mouse model [13]

Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces its participation in the upcoming Psychedelic Medicine – Israel 2024 conference. This event will take place in Tel Aviv, Israel from July 28th to 30th, bringing together leading experts and researchers from ...

Core Insights - Clearmind Medicine Inc. has received patent approval in Hong Kong for its MEAI-based binge behavior regulator program, enhancing its intellectual property portfolio in the psychedelic space [1] - The company now holds 28 granted patents across 18 patent families, with protections in major jurisdictions including the US, Europe, China, India, and Hong Kong [1][2] - MEAI is a novel psychoactive molecule aimed at reducing alcohol consumption and addressing Alcohol Use Disorder, which affects a significant number of individuals [5][6] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly alcohol use disorder [6] - The company plans to continue seeking additional patents and expanding its intellectual property portfolio opportunistically [2] Product Focus - The MEAI compound is designed to regulate binge behavior and may also be effective in treating binge drinking, a serious addiction [4][5] - The flagship treatment targets Alcohol Use Disorder and weight loss, which are prevalent health concerns [5]

Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office This latest patent builds upon Clearmind's broa ...

About Yissum Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders. Clearmind is responsible for the ongoing development and potential commercialization in line with regulatory guidelines.The agreement includes future milestone payments, royalties on future sales, and commitments to safeguard intellectual property rights. Clearmind is a clinical-stage psychedelic pharmaceutical biot ...